BridgeMD
Clinical trial Phase III to study whether magnesium sulfate improves nerve block in knee surgeries.
EU CTIS ID: 2024-518601-17-00
What this study is testing
Evaluate the efficacy of perineural magnesium sulfate in prolonging analgesia when administered as an adjuvant to the local anesthetic ropivacaine in total knee arthroplasty.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients scheduled for total knee arthroplasty due to gonarthrosis
- ASA I, II, and III patients of both sexes.
- Age between 18 and 80 years.
- Informed consent signed, accepting participation in the study.
You likely can't join if
- Allergy or intolerance to local anesthetics, morphine or its derivatives, magnesium sulfate.
- Patients with any condition that prevents the use of regional analgesia: anticoagulated, antiplatelet therapy, local or systemic infection.
- Patients with difficulty understanding study-related information and collaborating in pain assessment.
- Patients with major psychiatric pathology as per DSM-V.
- Pregnancy and/or breastfeeding.
- ASA IV Patients
See the full eligibility criteria
- Patients scheduled for total knee arthroplasty due to gonarthrosis
- ASA I, II, and III patients of both sexes.
- Age between 18 and 80 years.
- Informed consent signed, accepting participation in the study.
- Allergy or intolerance to local anesthetics, morphine or its derivatives, magnesium sulfate.
- Patients with any condition that prevents the use of regional analgesia: anticoagulated, antiplatelet therapy, local or systemic infection.
- Patients with difficulty understanding study-related information and collaborating in pain assessment.
- Patients with major psychiatric pathology as per DSM-V.
- Pregnancy and/or breastfeeding.
- ASA IV Patients
- Diabetes mellitus with the last glycated hemoglobin control greater than 7%.
- Patients with neuromuscular diseases.
- Morbid obesity.
- Fibromyalgia
- Myofascial pain syndrome.
- Patients with prior treatment with corticosteroids or calcium antagonists in the last three months.
- Patients with cardiovascular disease (congestive heart failure, severe valvular disease, symptomatic coronary artery disease, and/or congenital/anatomical heart abnormalities).
- Patients with severe renal, hepatic, or respiratory disease.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.